Matinas BioPharma Holdings, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 22.94 million compared to USD 21 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.1 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1789 USD | -1.43% | -4.69% | -17.25% |
Mar. 27 | Transcript : Matinas BioPharma Holdings, Inc., 2023 Earnings Call, Mar 27, 2024 | |
Mar. 27 | Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.25% | 44.87M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- MTNB Stock
- News Matinas BioPharma Holdings, Inc.
- Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023